Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer

Table 3 Overall survival and disease free survival according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio

	NLR		PLR
	Low (< 3.0)	High (≥ 3.0)	Low (< 160)	High (≥ 160)
Overall survival
Stage I
3-yr OS rate	97.0%	98.2%	99.3%	94.7%
5-yr OS rate	92.6%	91.9%	94.8%	87.3%
Stage II
3-yr OS rate	91.2%	89.2%	90.6%	90.1%
5-yr OS rate	86.1%	84.0%	84.3%	86.2%
Stage III
3-yr OS rate	79.6%	73.4%	82.1%	71.4%
5-yr OS rate	69.3%	60.9%	69.6%	61.9%
Stage IV
3-yr OS rate	39.8%	21.2%	33.9%	27.4%
5-yr OS rate	34.3%	18.1%	28.6%	23.8%
Disease free survival
Stage I
3-yr DFS rate	98.3%	97.4%	98.7%	96.6%
5-yr DFS rate	96.1%	95.6%	97.2%	93.3%
Stage II
3-yr DFS rate	88.5%	89.3%	87.8%	89.9%
5-yr DFS rate	84.7%	86.5%	83.5%	87.5%
Stage III
3-yr DFS rate	79.2%	78.1%	79.8%	77.2%
5-yr DFS rate	75.2%	68.6%	74.5%	70.5%
Stage IV
3-yr DFS rate	42.2%	30.3%	38.5%	34.5%
5-yr DFS rate	37.5%	26.8%	34.3%	30.4%

NLR: Neutrophil-to-lymphocyte-ratio; PLR: Platelet-to-lymphocyte-ratio; OS: Overall survival; DFS: Disease frees survival.